

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Multiple myeloma (MM)	Ubiquitin specific peptidase 7 (USP7; HAUSP)	<p><i>In vitro</i> and mouse studies suggest the USP7 inhibitor P5091 could help treat MM. In primary MM tumors, USP7 expression was greater than that in healthy tissues and correlated with poor survival. In MM cell lines and primary tumor cells, including those resistant to Velcade bortezomib, P5091 decreased cell viability compared with vehicle and/or Velcade. In three mouse models of MM, P5091 decreased tumor growth and increased survival compared with vehicle. Progenra Inc. participated in the study, and ongoing work at the company includes undisclosed preclinical studies of P5091 and its analogs.</p> <p>Takeda Pharmaceutical Co. Ltd.'s Millennium Pharmaceuticals Inc. unit and Johnson &amp; Johnson market Velcade, a small molecule dipeptide boronic acid proteasome inhibitor, to treat MM and mantle cell lymphoma (MCL). Hybrigenics S.A. has two USP7 inhibitors, HBX 19,818 and HBX 41,108, in preclinical development for chronic lymphocytic leukemia (CLL) and cancer, respectively.</p> <p><b>SciBX 5(37); doi:10.1038/scibx.2012.979</b>  <b>Published online Sept. 20, 2012</b></p>	Patent status undisclosed; available for licensing or partnering	<p>Chauhan, D. <i>et al. Cancer Cell</i>; published online Sept. 11, 2012; doi:10.1016/j.ccr.2012.08.007</p> <p><b>Contact:</b> Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.  e-mail: <a href="mailto:kenneth_anderson@dfci.harvard.edu">kenneth_anderson@dfci.harvard.edu</a></p> <p><b>Contact:</b> Dharminder Chauhan, same affiliation as above  e-mail: <a href="mailto:dharminder_chauhan@dfci.harvard.edu">dharminder_chauhan@dfci.harvard.edu</a></p>